DOV 216303

Drug Profile

DOV 216303

Alternative Names: DOV 216,303

Latest Information Update: 21 Apr 2008

Price : $50

At a glance

  • Originator Wyeth
  • Developer DOV Pharmaceutical
  • Class Antidepressants; Chlorobenzenes; Pyrrolidines; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 07 Dec 2006 Merck and DOV Pharmacueticals terminate their licensing agreement for DOV 216303; DOV regains all rights
  • 05 Oct 2005 Data from a media release have been added to the adverse events and Affective disorders therapeutic trials sections
  • 09 Aug 2004 Merck licensed the exclusive worldwide rights to DOV 216303 for the treatment of depression, anxiety and addiction
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top